Truist Financial Corp Acquires New Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Truist Financial Corp acquired a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCULFree Report) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 50,000 shares of the biopharmaceutical company’s stock, valued at approximately $427,000.

Several other institutional investors also recently bought and sold shares of OCUL. Mirae Asset Global Investments Co. Ltd. grew its holdings in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 1,015 shares during the last quarter. Capital Performance Advisors LLP purchased a new position in Ocular Therapeutix in the third quarter worth $70,000. Palumbo Wealth Management LLC purchased a new position in Ocular Therapeutix in the fourth quarter worth $100,000. Creative Planning acquired a new stake in shares of Ocular Therapeutix during the third quarter worth $182,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock worth $285,000 after buying an additional 3,347 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ocular Therapeutix

In related news, insider Donald Notman sold 6,301 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $7.84, for a total transaction of $49,399.84. Following the completion of the transaction, the insider now directly owns 204,563 shares in the company, valued at $1,603,773.92. The trade was a 2.99 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 over the last three months. Company insiders own 3.50% of the company’s stock.

Ocular Therapeutix Trading Up 9.6 %

NASDAQ:OCUL opened at $6.50 on Wednesday. Ocular Therapeutix, Inc. has a 12 month low of $4.06 and a 12 month high of $11.78. The firm has a fifty day simple moving average of $7.84 and a 200-day simple moving average of $8.90. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $1.02 billion, a P/E ratio of -4.92 and a beta of 1.22.

Ocular Therapeutix (NASDAQ:OCULGet Free Report) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). The business had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. On average, equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

View Our Latest Report on OCUL

Ocular Therapeutix Profile

(Free Report)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

See Also

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCULFree Report).

Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.